Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201350 | 1.00 | HRH3 (0.41) | HRH3HRH4NUDT1MAPTGFER | |
| SCHEMBL30834186 | 0.87 | HRH4 (0.38) | HRH3HRH4NUDT1MAPTGFER | |
| SCHEMBL27201456 | 0.87 | HRH4 (0.38) | HRH3HRH4NUDT1MAPTGFER | |
| SCHEMBL30834132 | 0.76 | HRH3 (0.45) | HRH3HRH4NUDT1MAPTGFER | |
| SCHEMBL27201269 | 0.76 | HRH3 (0.45) | HRH3HRH4NUDT1MAPTGFER | |
| SCHEMBL27201519 | 0.72 | HRH4 (0.49) | HRH3HRH4 | |
| SCHEMBL30834195 | 0.72 | HRH4 (0.49) | HRH3HRH4 | |
| SCHEMBL30885273 | 0.71 | HRH3 (0.39) | HRH3HRH4 | |
| SCHEMBL30834212 | 0.71 | HRH4 (0.53) | HRH3HRH4 | |
| SCHEMBL27201325 | 0.71 | HRH3 (0.39) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HRH3 4300/4885HRH4 4074/4885NUDT1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.